Cancer vaccines

Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs

Retrieved on: 
Wednesday, March 3, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Immunotherapy, Virotherapy, Cancer vaccine, Biotechnology, Cancer vaccines

PLYMOUTH MEETING, Pa., March 3, 2021 /PRNewswire/ -- Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today that it has closed its Series A1 round, raising $12 million in financing.

Key Points: 
  • PLYMOUTH MEETING, Pa., March 3, 2021 /PRNewswire/ -- Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today that it has closed its Series A1 round, raising $12 million in financing.
  • In conjunction with the financing, Mr. Sangwoo Lee, Managing Director Korea Investment Partners USA Inc. joined Geneos' Board of Directors.
  • "Geneos has made great strides in advancing the novel and differentiated GT-EPIC platform for personalized cancer treatments," commented Mr. Lee.
  • "The Series A1 financing demonstrates our investors' confidence in the GT-EPIC platform to design and manufacture patient-specific personalized cancer vaccines," said Dr. Niranjan Y. Sardesai, Founder and Chief Executive Officer of Geneos Therapeutics.

Increasing R&D Studies to Develop Cancer Vaccines Attributed to Spike in Number of Cancer Patients

Retrieved on: 
Thursday, February 18, 2021
Vaccination, Medical specialties, Clinical medicine, Cancer vaccines, Medicine, Vaccines, Virology, Vaccine, Therapeutic vaccines, Cancer vaccine, HPV vaccine, Cancer prevention

Ovarian cancer is regarded as one of the most common types of cancer among women.

Key Points: 
  • Ovarian cancer is regarded as one of the most common types of cancer among women.
  • The report said that: "(The) growth of the cancer vaccines market is attributed to rise in number of cancer patients across the globe.
  • Furthermore, rise in public awareness toward benefits of cancer vaccines, surge in demand for cancer vaccines, and rise in adoption rate of preventive and therapeutic vaccines are other factors that contribute toward growth of the market."
  • Moreover, rise in adoption rates of preventive and therapeutic vaccines, technological advancements in cancer vaccines, increase in number of cancer cases, and launch of novel cancer vaccines further boost the cancer vaccines market growth Furthermore, growth in transition from prophylactic to therapeutic cancer vaccines is expected to offer lucrative opportunities in the near future."

Increasing R&D Studies to Develop Cancer Vaccines Attributed to Spike in Number of Cancer Patients

Retrieved on: 
Thursday, February 18, 2021
Vaccination, Medical specialties, Clinical medicine, Cancer vaccines, Medicine, Vaccines, Virology, Vaccine, Therapeutic vaccines, Cancer vaccine, HPV vaccine, Cancer prevention

Ovarian cancer is regarded as one of the most common types of cancer among women.

Key Points: 
  • Ovarian cancer is regarded as one of the most common types of cancer among women.
  • The report said that: "(The) growth of the cancer vaccines market is attributed to rise in number of cancer patients across the globe.
  • Furthermore, rise in public awareness toward benefits of cancer vaccines, surge in demand for cancer vaccines, and rise in adoption rate of preventive and therapeutic vaccines are other factors that contribute toward growth of the market."
  • Moreover, rise in adoption rates of preventive and therapeutic vaccines, technological advancements in cancer vaccines, increase in number of cancer cases, and launch of novel cancer vaccines further boost the cancer vaccines market growth Furthermore, growth in transition from prophylactic to therapeutic cancer vaccines is expected to offer lucrative opportunities in the near future."

Ultimovacs Starts Clinical Evaluation of Novel TET-Platform with Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine

Retrieved on: 
Thursday, February 18, 2021
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Vaccination, Virology, Medicine, Vaccine, Clinical medicine, Vaccines, Cancer vaccines, Medical research, the TENDU trial, the TET-Technology, Ultimovacs

Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation for the Companys Tetanus-Epitope Targeting (TET)-platform.

Key Points: 
  • Ultimovacs ASA ("Ultimovacs", ticker ULTI), today announced the treatment of the first patient in the Phase I TENDU trial, representing the start of clinical evaluation for the Companys Tetanus-Epitope Targeting (TET)-platform.
  • The TENDU clinical trial, conducted at the Oslo University Hospital, is a first-in-human, dose-escalation study designed to generate initial safety and immune activation data for a prostate cancer-specific therapeutic TET-based vaccine in relapsed prostate cancer patients.
  • The TENDU clinical trial is a first-in-human, Phase I study and the first clinical trial resulting from Ultimovacs Tetanus-Epitope Targeting (TET)-platform.
  • In addition to its universal vaccine, UV1, Ultimovacs is developing novel vaccine products based on the patent-protected Tetanus-Epitope Targeting (TET)-platform.

Global Human Papillomavirus (HPV) Vaccines Analysis Report 2021: Supplemental Approvals Boost Opdivo And Gardasil 9, But Limit Beovu

Retrieved on: 
Wednesday, February 17, 2021
Papillomavirus, Clinical medicine, Vaccination, Medicine, Vaccines, Cancer vaccines, Infectious causes of cancer, Cervarix, Gardasil, Human papillomavirus infection, Virus-like particle, HPV vaccine

DUBLIN, Feb. 17, 2021 /PRNewswire/ -- The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 17, 2021 /PRNewswire/ -- The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • There are currently three approved vaccines for HPV: Cervarix, Gardasil, and Gardasil 9.
  • Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs).
  • In 2014, Gardasil 9, a nine-valent vaccine capable of protecting from an additional 20% of HPV-related cancers, superseded Gardasil.

Global Dendritic Cell Cancer Vaccine Immunotherapy Clinical Trials Market Insight 2026

Retrieved on: 
Wednesday, February 17, 2021
Medical specialties, Clinical medicine, Medicine, Vaccination, Cancer vaccines, Vaccines, Cancer immunotherapy, Immunotherapy, Virotherapy, Vaccine, Cancer vaccine, Dendritic cell

NEW DELHI, Feb. 17, 2021 /PRNewswire/ -- "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, Feb. 17, 2021 /PRNewswire/ -- "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:
    Global Dendritic Cell Cancer Vaccine Clinical Trials: More than 50 Vaccines In Pipeline
    Commercially Available Dendritic Cell Cancer Vaccine: 3 Vaccines
    Dendritic Cell Cancer Vaccine Expected Launches Over Next Decade: More Than 3 Vaccines
    Majority Vaccines In Preclinical Phase: More Than 10 Vaccines
    Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
    Global dendritic cell cancer vaccine immunotherapy for the patients is estimated to deliver ample trends and opportunities as well as experiences that are life-changing for the patients who will receive the drugs that will be available within the market.
  • As per the extensive research conducted for current market trend and opportunities, it is estimated that the therapy in a very progressive way could transform the entire cancer therapeutics market towards the benefits of immunotherapy.
  • Some of the current drivers found to be the reason for accelerating the market are: successful implication of immunotherapy applications among the cancer patients, high-failure rate of other therapies, increased prevalence and mortality rate of cancer and increased awareness of the patient population towards successful clinical investigations for dendritic cell cancer vaccine immunotherapy all across the globe.
  • The performance of the therapy is now getting reflected as a top emerging leader, thus leaning the entire cancer therapeutics market towards the applications of dendritic cell cancer vaccine immunotherapy which subsequently involves dendritic cell, an important cell of immune system for generating a strong immune response against the cancer cells.

Global Dendritic Cell Cancer Vaccine Immunotherapy Clinical Trials Market Insight 2026

Retrieved on: 
Wednesday, February 17, 2021
Medical specialties, Clinical medicine, Medicine, Vaccination, Cancer vaccines, Vaccines, Cancer immunotherapy, Immunotherapy, Virotherapy, Vaccine, Cancer vaccine, Dendritic cell

NEW DELHI, Feb. 17, 2021 /PRNewswire/ -- "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

Key Points: 
  • NEW DELHI, Feb. 17, 2021 /PRNewswire/ -- "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:
    Global Dendritic Cell Cancer Vaccine Clinical Trials: More than 50 Vaccines In Pipeline
    Commercially Available Dendritic Cell Cancer Vaccine: 3 Vaccines
    Dendritic Cell Cancer Vaccine Expected Launches Over Next Decade: More Than 3 Vaccines
    Majority Vaccines In Preclinical Phase: More Than 10 Vaccines
    Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
    Global dendritic cell cancer vaccine immunotherapy for the patients is estimated to deliver ample trends and opportunities as well as experiences that are life-changing for the patients who will receive the drugs that will be available within the market.
  • As per the extensive research conducted for current market trend and opportunities, it is estimated that the therapy in a very progressive way could transform the entire cancer therapeutics market towards the benefits of immunotherapy.
  • Some of the current drivers found to be the reason for accelerating the market are: successful implication of immunotherapy applications among the cancer patients, high-failure rate of other therapies, increased prevalence and mortality rate of cancer and increased awareness of the patient population towards successful clinical investigations for dendritic cell cancer vaccine immunotherapy all across the globe.
  • The performance of the therapy is now getting reflected as a top emerging leader, thus leaning the entire cancer therapeutics market towards the applications of dendritic cell cancer vaccine immunotherapy which subsequently involves dendritic cell, an important cell of immune system for generating a strong immune response against the cancer cells.

Global Human Papillomavirus (HPV) Vaccines Disease Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 12, 2021
Biotechnology, Infectious diseases, Other Health, Health, Pharmaceutical, Papillomavirus, Clinical medicine, Medical specialties, Vaccination, Vaccines, Cancer vaccines, Infectious causes of cancer, Gardasil, Human papillomavirus infection, Papillomaviridae, HPV vaccine, Virus-like particle

The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: Human Papillomavirus (HPV) Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • Worldwide vaccination programs for human papillomavirus (HPV) have evolved substantially over the last decade.
  • Both vaccines are based on the recombinant expression of major capsid antigen L1 from different HPV serotypes, which self-assemble into virus-like particles (VLPs).
  • In 2014, Gardasil 9, a nine-valent vaccine capable of protecting from an additional 20% of HPV-related cancers, superseded Gardasil.

Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa

Retrieved on: 
Friday, February 12, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Immunotherapy, Virotherapy, Medical specialties, Cancer vaccines, Immunology, Immune system

TYG100 is an antigen-specific, active checkpoint control immunotherapy(ACCI) recombinant vaccine comprising the amino-terminal sequence of G17, a gastrointestinal peptide hormone, and utilizes the S-TIR technology platform.

Key Points: 
  • TYG100 is an antigen-specific, active checkpoint control immunotherapy(ACCI) recombinant vaccine comprising the amino-terminal sequence of G17, a gastrointestinal peptide hormone, and utilizes the S-TIR technology platform.
  • TYG oncology originally co-developed TYG100 with Nuance Biotech and this license is now assigned to Apollomics for further co-development.
  • TYG100 represents the new era of active checkpoint control immunotherapy by enabling a rapid and appropriate natural immune response, said Guo-Liang Yu, Ph.D., Chief Executive Officer of Apollomics.
  • Under the terms of the agreement, Apollomics will be responsible for clinical development and commercialization in Greater China and South Africa.

Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa

Retrieved on: 
Friday, February 12, 2021
Clinical medicine, Medicine, Cancer immunotherapy, Virotherapy, Medical specialties, Cancer vaccines, Immunotherapy, Immunology

TYG100 is an antigen-specific, active checkpoint control immunotherapy (ACCI) recombinant vaccine comprising the amino-terminal sequence of G17, a gastrointestinal peptide hormone, and utilizes the S-TIR(TM) technology platform.

Key Points: 
  • TYG100 is an antigen-specific, active checkpoint control immunotherapy (ACCI) recombinant vaccine comprising the amino-terminal sequence of G17, a gastrointestinal peptide hormone, and utilizes the S-TIR(TM) technology platform.
  • "TYG100 represents the new era of active checkpoint control immunotherapy by enabling a rapid and appropriate natural immune response," said Guo-Liang Yu, Ph.D., Chief Executive Officer of Apollomics.
  • Under the terms of the agreement, Apollomics will be responsible for clinical development and commercialization in Greater China and South Africa.
  • TYG100 is an active checkpoint control immunotherapy (ACCI) recombinant vaccine that targets the gastrin immunogen.